Abstract: The present disclosure is directed to antibodies binding previously undefined epitopes on influenza A virus hemagglutinin and methods for use thereof.

Abstract: The present disclosure is directed to antibodies binding to and neutralizing the coronavirus designated SARS-CoV-2 and methods for use thereof.

Abstract: The present disclosure is directed to antibodies binding to and neutralizing norovirus and methods for use thereof. Thus, in accordance with the present disclosure, there is provided a method of detecting a norovirus infection in a subject comprising (a) contacting a sample from the subject with an antibody or antibody fragment having clone-paired heavy and light chain CDR sequences; and (b) detecting norovirus in the sample by binding of the antibody or antibody fragment to a norovirus antigen in the sample.

Abstract: The present disclosure is directed to antibodies binding to and neutralizing Crimean Congo Hemorrhagic Fever Virus and methods for use thereof.

Abstract: The present disclosure is directed to an antibody cocktail comprising antibodies that bind to and protect subjects again multiple ebolavirus strains and methods for use thereof.

Abstract: The present disclosure is directed to antibodies binding to and neutralizing Yellow Fever Virus and methods for use thereof.

Abstract: The present disclosure is directed to antibodies binding to and neutralizing West Nile virus and methods for use thereof.

Abstract: The present disclosure is directed to antibodies binding to and inhibiting S. aureus and methods for use thereof.

Abstract: The present disclosure is directed to antibodies binding to and neutralizing Japanese Encephalitis virus and methods for use thereof.

Abstract: The present disclosure is directed to human antibodies binding to and neutralizing ebolavirus and methods for use thereof. A further embodiment involves a monoclonal antibody, wherein the antibody or antibody fragment is characterized by clone-paired heavy and light chain CDR sequences. In yet another embodiment, there is provided a hybridoma or engineered cell encoding an antibody or antibody fragment. An additional embodiment comprises a vaccine formulation comprising one or more antibodies or antibody fragments characterized by clone-paired heavy and light chain CDR sequences. In still a further embodiment, there is provided a method of protecting the health of a placenta and/or fetus of a pregnant a subject infected with or at risk of infection with ebolavirus comprising delivering to said subject the antibody or antibody fragment.

Abstract: The present disclosure is directed to antibodies binding to and neutralizing Chikungunya virus (CHIKV) and methods for use thereof.

Abstract: Provided herein are novel monoclonal antibodies and antibody fragments with improved binding to and/or neutralization against multiple SARS-CoV-2 variants, e.g., Omicron lineages. Also provided are compositions and biosensors comprising the monoclonal antibodies and antibody fragments and methods of using the novel monoclonal antibodies and antibody fragments for treating, preventing, and diagnosing COVID-19 and detecting SARS-CoV-2.

Abstract: The present disclosure relates to antibodies and uses thereof for treating, preventing, and detecting coronavirus infection.

Abstract: This disclosure relates to compositions and methods for treating and preventing chikungunya virus infection by delivering polynucleotides encoding anti-chikungunya virus antibodies to a subject. Compositions and treatments provided herein include one or more polynucleotides having an open reading frame encoding an anti-chikungunya virus antibody heavy chain or fragment thereof and/or an anti-chikungunya virus antibody light chain or fragment thereof. Methods for preparing and using such treatments are also provided.

Abstract: The present disclosure is directed to antibodies binding to and neutralizing Zika virus and methods for use thereof.

Abstract: The present disclosure is directed to antibodies binding to and neutralizing Venezuelan Equine Encephalitis Vims (VEEV) and methods for use thereof.

Abstract: The present disclosure is directed to antibodies binding to and neutralizing Poxvirus and methods for use thereof.

Abstract: The present disclosure is directed to antibodies binding to and neutralizing tire coronavirus designated SARS-CoV-2 and methods for use thereof.

Abstract: The present disclosure is directed to antibodies binding to and neutralizing Zika vims and methods for use thereof.

Abstract: The present disclosure is directed to antibodies binding to and neutralizing dengue virus and methods for use thereof.